share_log

Virpax Pharmaceuticals | CORRESP: CORRESP

Virpax Pharmaceuticals | CORRESP: CORRESP

Virpax制药 | CORRESP:信函
美股SEC公告 ·  05/03 12:35

Moomoo AI 已提取核心信息

Virpax Pharmaceuticals, Inc. has formally withdrawn its request to accelerate the effective date of its Registration Statement on Form S-1, initially filed on April 18, 2024. The company had previously sought to expedite the process with a request filed on May 2, 2024, for the Registration Statement to be effective by May 2, 2024, at 5:00 p.m. Eastern Time. However, in a correspondence to the SEC dated May 3, 2024, Virpax's CEO Gerald Bruce indicated the company is no longer pursuing the accelerated effective date and has retracted the request. The correspondence was addressed to Daniel Crawford at the SEC's Division of Corporation Finance.
Virpax Pharmaceuticals, Inc. has formally withdrawn its request to accelerate the effective date of its Registration Statement on Form S-1, initially filed on April 18, 2024. The company had previously sought to expedite the process with a request filed on May 2, 2024, for the Registration Statement to be effective by May 2, 2024, at 5:00 p.m. Eastern Time. However, in a correspondence to the SEC dated May 3, 2024, Virpax's CEO Gerald Bruce indicated the company is no longer pursuing the accelerated effective date and has retracted the request. The correspondence was addressed to Daniel Crawford at the SEC's Division of Corporation Finance.
Virpax药品公司正式撤回了其在2024年4月18日首次提交的S-1表格注册声明的加速生效日期的申请。该公司此前曾在2024年5月2日提交了一份请求,要求将注册声明在东部时间2024年5月2日下午5:00之前生效,以加快流程。然而,在2024年5月3日致美国证券交易委员会的一封信中,Virpax的CEO杰拉尔德·布鲁斯表示该公司不再追求加速生效日期,并已撤回该请求。这封信是在致SEC公司金融部门的丹尼尔·克劳福德的信中提到的。
Virpax药品公司正式撤回了其在2024年4月18日首次提交的S-1表格注册声明的加速生效日期的申请。该公司此前曾在2024年5月2日提交了一份请求,要求将注册声明在东部时间2024年5月2日下午5:00之前生效,以加快流程。然而,在2024年5月3日致美国证券交易委员会的一封信中,Virpax的CEO杰拉尔德·布鲁斯表示该公司不再追求加速生效日期,并已撤回该请求。这封信是在致SEC公司金融部门的丹尼尔·克劳福德的信中提到的。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息